Applicant: Gregory J. LaRosa et al. Attorney's Docket No.: 10448-215011 / MPI98-129CN1B

Serial No.: 10/826,454 Filed : April 16, 2004

Page : 2 of 5

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## **Listing of Claims:**

## 1.-10. (Cancel)

- 11. (Original) A test kit for use in detecting the presence of a mammalian CC-chemokine receptor 2 in a biological sample comprising
  - at least one antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 2, wherein said antibody or antigen-binding fragment thereof inhibits binding of a ligand to the receptor; and
  - **b**) one or-more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen-binding fragment thereof and said mammalian CC-chemokine receptor 2 or a portion thereof.

## 12.-43. (Cancel)

- 44. (New) The kit according to Claim 1, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to the receptor.
- 45. (New) The kit according to Claim 1, wherein said antibody or antigen-binding fragment thereof binds to a human CC-chemokine receptor 2.
- 46. (New) The kit according to Claim 1, wherein said antibody or antigen-binding

Applicant: Gregory J. LaRosa et al. Attorney's Docket No.: 10448-215011 / MPI98-

Serial No.: 10/826,454 129CN1B

Filed. : April 16, 2004

Page : 3 of 5

fragment thereof inhibits binding of a chemokine to the receptor.

47. (New) The kit according to Claim 4, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP4 and combinations thereof.

- 48. (New) The kit according to Claim 1, wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or fragment thereof.
- 49. (New) The kit according to Claim 1, wherein said antibody or antigen-binding fragment thereof is a human antibody or fragment thereof
- 50. (New) The kit according to Claim 1, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab fragment and an F(ab')<sub>2</sub> fragment.
- 51. (New) The kit according to Claim 1, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or fragment thereof.
- 52. (New) The kit according to Claim 1, wherein said antibody or antigen-binding fragment thereof is a recombinant antibody or fragment thereof.
- 53. (New) The kit according to Claim 1, further comprising a second antibody or antigen-binding fragment thereof specific for a different epitope of the receptor than the said antibody or antigen-binding fragment thereof.
- 54. (New) The kit according to claim 53, wherein the second antibody or antigen-binding fragment thereof is labeled.
- 55. (New) The kit according to Claim 1, further comprising a second antibody or antigenbinding fragment thereof which binds said antibody or antigen-binding portion thereof.

Applicant: Gregory J. LaRosa et al. Attorney's Docket No.: 10448-215011 / MPI98-

Serial No.: 10/826,454 Filed: April 16, 2004

Page : 4 of 5

56. (New) The kit according to Claim 55, wherein the second antibody or antigen-binding fragment thereof is labeled.

129CN1B

- 57. (New) The kit according to Claim 1, wherein the antibody or antigen-binding fragment thereof is lyophilized.
- 58. (New) The kit according to Claim 57, further comprising an acceptable diluent, excipient or carrier.